[{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dichlorphenamide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Torrent Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dichlorphenamide","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Torrent Pharmaceuticals Limited \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Torrent Pharmaceuticals Limited \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Torrent Pharmaceuticals Limited \/ Torrent Pharmaceuticals Limited"}]

Find Clinical Drug Pipeline Developments & Deals by Torrent Pharmaceuticals Limited

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. It is indicated for cystinuria.

                          Brand Name : Tiopronin-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 13, 2024

                          Lead Product(s) : Tiopronin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved

                          Recipient : Cycle Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Ormalvi (dichlorphenamide) is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.

                          Brand Name : Ormalvi

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 08, 2024

                          Lead Product(s) : Dichlorphenamide

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Cycle Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.

                          Brand Name : Keveyis-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 06, 2023

                          Lead Product(s) : Dichlorphenamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank